fda safety communication semaglutide naion 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" GLP-1 Receptor Agonists and vision

Patients with diabetes taking semaglutide should be particularly vigilant, as they may experience atypical or less pronounced symptoms due to diabetic neuropathy affecting sensory perception

Dalle Grave R

Research on GLP-1 Use in People With Bipolar Disorder Is Limited The original randomized, controlled trials for GLP-1s often didnt include participants with bipolar disorder, notes the nonprofit International Bipolar Foundation

Your Health and Safety Come First At Dr

What other weight loss medications are available in Canada

Rai said the additional five years, stretching the patent from 2026 to 2031, likely stem from the Hatch-Waxman Act, a 1984 law that allows drugmakers to extend patents by up to five years to make up for time lost moving their drug through clinical trials and the FDA approval process